TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05408975

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Transcranial direct current stimulation
Description: Transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. Stimulation will consist of 1 milliamp stimulation, with anodal stimulation delivered at electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, then remain at 1 milliamp of stimulation over 20 minutes, and finally ramping down at to 0 milliamps over 60 seconds.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Transcranial direct current stimulation
Description: Transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. Stimulation will consist of 1 milliamp stimulation, with anodal stimulation delivered at electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, then remain at 1 milliamp of stimulation over 20 minutes, and finally ramping down at to 0 milliamps over 60 seconds.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Transcranial direct current stimulation
Description: Sham transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. The sham setup will consist of anodal electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, ramp down to 0 milliamps over 60 seconds and then be left off for 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Transcranial direct current stimulation
Description: Sham transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. The sham setup will consist of anodal electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, ramp down to 0 milliamps over 60 seconds and then be left off for 20 minutes.
Study: NCT04556890

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active rTMS/Active iTBS DFPLC/Sham Pain M1
Description: Active rTMS treatment for depression (600 pulses of active intermittent theta burst (iTBS) administrated at 120% MT to the left DLPFC) and sham treatment for pain at M1

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active rTMS/Active iTBS
Description: Active rTMS treatment for both, depression and pain (600 pulses of iTBS to left DLPFC followed by 600 iTBS + 1500 pulses of 10 Hz to M1
Study: NCT06692491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-Bound Paclitaxel
Description: Albumin-Bound Paclitaxel 260mg/m2,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with albumin-bound paclitaxel if PDOs show the highest response to this drug under the guidance of MTB.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin 90mg/m2,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with epirubicin if PDOs show the highest response to this drug under the guidance of MTB.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin 90mg/m2,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with epirubicin if PDOs show the highest response to this drug under the guidance of MTB.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000mg/m2,D1,D8,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with gemcitabine if PDOs show the highest response to this drug under the guidance of MTB.
Study: NCT05451329

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VVN539 Ophthalmic Solution 0.02%
Description: Once a day \[q.d.\] in the morning, q.d. in the evening and twice a day \[b.i.d.\]) will be tested for 7-9 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VVN539 Ophthalmic Solution 0.04%
Description: Once a day \[q.d.\] in the morning, q.d. in the evening and twice a day \[b.i.d.\]) will be tested for 7-9 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VVN539 Ophthalmic Solution Vehicle
Description: Once a day \[q.d.\] in the morning, q.d. in the evening and twice a day \[b.i.d.\]) will be tested for 7-9 days
Study: NCT05274698

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: muscle energy technique
Description: It is a manual treatment in which a patient produces a contraction in a precisely controlled position and direction against a counterforce applied by a manual therapist .Muscle energy techniques (MET) were originally developed to treat soft tissue, mobilize joints, stretch tight muscles and fascia, reduce pain and to improve circulation and lymphatic drainage.
Study: NCT06692491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000mg/m2,D1,D8,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with gemcitabine if PDOs show the highest response to this drug under the guidance of MTB.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinorelbine 25-30mg/m2,D1,D8,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with vinorelbine if PDOs show the highest response to this drug under the guidance of MTB.
Study: NCT05727904

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lifileucel plus Pembrolizumab
Description: A tumor sample is resected from each patient for Lifileucel manufacturing. Patients then receive Pembrolizumab followed by the lifileucel regimen which consists of non-myeloablative lymphodepletion, lifileucel infusion followed by IL-2. Patients will then continue to receive Pembrolizumab every 6 weeks until disease progression.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab with Optional Crossover Period
Description: Patient will receive Pembrolizumab monotherapy every 6 weeks until disease progression. Upon verified confirmed disease progression by the blinded independent review central committee, patients may proceed to lifileucel monotherapy during an optional crossover period if they meet eligibility criteria.~Optional crossover: A tumor sample is resected from each patient for Lifileucel manufacturing. Patients then receive the lifileucel regimen which consists of non-myeloablative lymphodepletion, lifileucel infusion followed by IL-2.
Study: NCT05423730

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White Wine
Description: One serving (5 ounces) of white wine daily for 3 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White Wine
Description: One serving (5 ounces) of white wine daily for 3 weeks
Study: NCT06692491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinorelbine 25-30mg/m2,D1,D8,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with vinorelbine if PDOs show the highest response to this drug under the guidance of MTB.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 90mg/m2,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with cisplatin if PDOs show the highest response to this drug under the guidance of MTB.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 90mg/m2,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with cisplatin if PDOs show the highest response to this drug under the guidance of MTB.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 125mg/m2,D1,D8,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with irinotecan if PDOs show the highest response to this drug under the guidance of MTB.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 125mg/m2,D1,D8,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with irinotecan if PDOs show the highest response to this drug under the guidance of MTB.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Fluorouracil 600mg/m2,D1-5,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with fluorouracil if PDOs show the highest response to this drug under the guidance of MTB.
Study: NCT05423730

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grape Juice
Description: One serving (6 ounces) of white grape juice daily for 3 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grape Juice
Description: One serving (6 ounces) of white grape juice daily for 3 weeks
Study: NCT06238661

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urology visit with Risk Calculator and MRI
Description: Patients with PSA ≥3 ng/ml will undergo urology visit with risk calculator and MRI assessment of the prostate
Study: NCT06576427

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vertex Pulmonary Embolectomy System
Description: Use of Vertex Pulmonary Embolectomy System to treat pulmonary embolism.
Study: NCT05736224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunscreen
Description: The sunscreen contains bioadhesive nanoparticles (BNP) encapsulating avobenzone and octocrylene plus the non-toxic natural products diosmin, ferulic acid, cytisine and trans-resveratrol.

Intervention type: OTHER
Group type: OTHER
Intervention: UV Light
Description: UV light to the correct sites, and the Multiport 610 solar simulator used to deliver 1 MED UVR to the appropriate subsites.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UV Light
Description: UV light to the correct sites, and the Multiport 610 solar simulator used to deliver 1 MED UVR to the appropriate subsites.
Study: NCT05274698

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: conventional physical therapy program (Mobilization exercises, Posterior capsule stretching, and Range of motion exercises) 1 session per day, 5 days a week for 8 weeks.
Description: Joint mobilization, specifically glenohumeral joint distraction, glenohumeral joint caudal glide, glenohumeral joint posterior glide, and glenohumeral joint anterior glide, will be applied with patients.~Posterior capsule stretching will be applied with patients in side lying position. The scapula will be stabilized at the lateral side with the arm at 90° flexion. Stretching will be applied from the elbow with a downward force. The stretch will be repeated 10 times for 20 s each. A 30-s break will be given between each stretching .~Range of motion exercises:~Codman/ pendulum exercise ,Wall climbing exercise and Shoulder wheel exercise Circumduction of the shoulder joint clockwise and anticlockwise using shoulder wheel
Study: NCT06613958

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physical activity timing
Description: The investigators will compare our interventions to a 14-day period of sedentary behavior, during which the participant will refrain from any moderate to vigorous exercise. Next, participants will participate in two interventions consisting each of a 14-day physical activity regimen. The active morning and active evening interventions are equal in content. Both groups will be instructed to refrain from any moderate to vigorous exercise for the rest of the day. Per intervention, a total of eight Vitality Club training session comprising of a combination of aerobic endurance training and resistance exercise training will be given by a trained sports coach or physical therapist specialized in geriatric physical therapy. During the weekends, participants will be asked to perform a 'relative rest' session with some light activity during the training time window of the intervention arm.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physical activity timing
Description: The investigators will compare our interventions to a 14-day period of sedentary behavior, during which the participant will refrain from any moderate to vigorous exercise. Next, participants will participate in two interventions consisting each of a 14-day physical activity regimen. The active morning and active evening interventions are equal in content. Both groups will be instructed to refrain from any moderate to vigorous exercise for the rest of the day. Per intervention, a total of eight Vitality Club training session comprising of a combination of aerobic endurance training and resistance exercise training will be given by a trained sports coach or physical therapist specialized in geriatric physical therapy. During the weekends, participants will be asked to perform a 'relative rest' session with some light activity during the training time window of the intervention arm.
Study: NCT06613581

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based follow-up
Description: Follow-up after surgery for colorectal carcinoma, performed from home, within the bounds of the Dutch National guidelines
Study: NCT06207318

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy
Description: The intervention will be based on Acceptance and Commitment Therapy (ACT). ACT is an empirically-based therapeutic approach that focuses on psychological flexibility, acceptance, and the reduction of experiential avoidance. It encourages individuals to change their relating to thoughts and experiences and act in accordance with their values.
Study: NCT06696183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib (GILT)
Description: 80 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib (GILT)
Description: 80 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib (GILT)
Description: 80 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib (GILT)
Description: 80 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax (VEN)
Description: 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax (VEN)
Description: 400 mg
Study: NCT05274698

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: conventional physical therapy program (Mobilization exercises, Posterior capsule stretching, and Range of motion exercises) 1 session per day, 5 days a week for 8 weeks.
Description: Joint mobilization, specifically glenohumeral joint distraction, glenohumeral joint caudal glide, glenohumeral joint posterior glide, and glenohumeral joint anterior glide, will be applied with patients.~Posterior capsule stretching will be applied with patients in side lying position. The scapula will be stabilized at the lateral side with the arm at 90° flexion. Stretching will be applied from the elbow with a downward force. The stretch will be repeated 10 times for 20 s each. A 30-s break will be given between each stretching .~Range of motion exercises:~Codman/ pendulum exercise ,Wall climbing exercise and Shoulder wheel exercise Circumduction of the shoulder joint clockwise and anticlockwise using shoulder wheel
Study: NCT06575309

Intervention type: BIOLOGICAL
Intervention: Blood test
Description: The procedures added as part of this research are 6 blood samples, the volumes of which do not exceed the volume authorized in the order of February 17, 2021, i.e. 27mL.
Study: NCT05411614

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AtriCure EPi-Sense-AF Guided Coagulation System +/- Atriclip
Description: Minimally-invasive epicardial ablation +/- left atrial appendage exclusion using an epicardial clip, combined with endocardial radiofrequency catheter ablation
Study: NCT06692491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Fluorouracil 600mg/m2,D1-5,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with fluorouracil if PDOs show the highest response to this drug under the guidance of MTB.
Study: NCT05411614

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endocardial Catheter Ablation
Description: Standard percutaneous endocardial catheter ablation of atrial fibrillation
Study: NCT06692491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3mg/kg,q2w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with nivolumab under the guidance of MTB.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3mg/kg,q2w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with nivolumab under the guidance of MTB.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200mg,q2w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with pembrolizumab under the guidance of MTB.
Study: NCT05411614

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endocardial Catheter Ablation
Description: Standard percutaneous endocardial catheter ablation of atrial fibrillation
Study: NCT06378125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: controlled-ileal-release nicotinic acid (SAD/ MAD/MD) single- and multiple-ascending dose (SAD/MAD) or multiple dose (MD)
Description: A double-blind, randomised, placebo-controlled, single-ascending and multiple-ascending dose trial to evaluate the safety and pharmacokinetics of oral controlled-ileal-release nicotinic acid (CIR-NA) compared to immediate-release nicotinic acid and placebo in healthy subjects and subjects with prediabetes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: controlled-ileal-release nicotinic acid (SAD/ MAD/MD) single- and multiple-ascending dose (SAD/MAD) or multiple dose (MD)
Description: A double-blind, randomised, placebo-controlled, single-ascending and multiple-ascending dose trial to evaluate the safety and pharmacokinetics of oral controlled-ileal-release nicotinic acid (CIR-NA) compared to immediate-release nicotinic acid and placebo in healthy subjects and subjects with prediabetes.
Study: NCT05205096

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant novel coronavirus vaccine (CHO cells)
Description: At 3-9 months after the immunization with 2 doses of inactivated vaccine (CoronaVac), 1 dose of recombinant novel coronavirus vaccine (CHO cells) is vaccinated.
Study: NCT05435833

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bilateral ultrasound guided GPN block
Description: a linear high frequency ultrasound probe will be initially positioned over the hyoid bone in the transverse plane, then the probe will be rotated to keep in line with the mandibular angle and the pharyngeal wall is identified by US. Using an in plane approach, a 22 G ,5 cm needle will be advanced till it reaches just superficial to the pharyngeal wall and 2.2 ml of 0.25% bupivacaine will be injected.
Study: NCT06378125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: immediate-release nicotinic acid (SAD)
Description: A double-blind, randomised, placebo-controlled, single-ascending and multiple-ascending dose trial to evaluate the safety and pharmacokinetics of oral controlled-ileal-release nicotinic acid (CIR-NA) compared to immediate-release nicotinic acid and placebo in healthy subjects and subjects with prediabetes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo controlled-ileal-release nicotinic acid (SAD/MAD)
Description: A double-blind, randomised, placebo-controlled, single-ascending and multiple-ascending dose trial to evaluate the safety and pharmacokinetics of oral controlled-ileal-release nicotinic acid (CIR-NA) compared to immediate-release nicotinic acid and placebo in healthy subjects and subjects with prediabetes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo immediate-release nicotinic acid (SAD)
Description: A double-blind, randomised, placebo-controlled, single-ascending and multiple-ascending dose trial to evaluate the safety and pharmacokinetics of oral controlled-ileal-release nicotinic acid (CIR-NA) compared to immediate-release nicotinic acid and placebo in healthy subjects and subjects with prediabetes.
Study: NCT05708846

Intervention type: OTHER
Intervention: Telemonitoring
Description: All patients will be telemonitored in order to create a labeled and diverse dataset that will include the following data:~Physiological parameters (measured periodically), socio-demographic data, risk factors, medication tracking, symptomatology questionnaire for patients, NYHA-class, clinical interventions, health questionnaire answers, classified alarms with their respective timestamp and annotation by the MD, and measurement ranges for each personalized alarm and their changes
Study: NCT05093335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]-Pentixafor
Description: An intravenous bolus of 3 -5 mCi of \[68Ga\]-Pentixafor will be injected in all participants.
Study: NCT05925075

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung Ultrasound
Description: Lung ultrasound to be performed at scheduled intervals as described in individual cohorts.

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung Ultrasound
Description: Lung ultrasound to be performed at scheduled intervals as described in individual cohorts.

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung Ultrasound
Description: Lung ultrasound to be performed at scheduled intervals as described in individual cohorts.
Study: NCT05907122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP 206
Description: ABP 206 will be given intravenously over a period of 30 minutes, every 4 weeks (Q4W) for a total of 12 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FDA-licensed Nivolumab
Description: FDA-licensed Nivolumab will be given intravenously over a period of 30 minutes, Q4W for a total of 12 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU-authorized Nivolumab
Description: FDA-licensed Nivolumab will be given intravenously over a period of 30 minutes, Q4W for a total of 12 months.
Study: NCT04890067

Intervention type: OTHER
Intervention: Treatment of Osteosarcoma according the AIEOP/ISG OS 2021 recommendations (includes drugs, surgery, radiotherapy or any other received treatments)
Description: This observational study collects all the treatments received by the patients according according the AIEOP/ISG OS 2021 and therefore includes drug/biological/surgical/ radiotherapy and any other applicable treatments